 Sachin Wani
Concepts (553)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 98 | 2024 | 147 | 30.730 |
Why?
| | Esophageal Neoplasms | 73 | 2024 | 273 | 21.240 |
Why?
| | Adenocarcinoma | 59 | 2024 | 795 | 11.280 |
Why?
| | Endosonography | 36 | 2023 | 140 | 9.670 |
Why?
| | Esophagoscopy | 51 | 2024 | 184 | 9.550 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 35 | 2024 | 180 | 9.470 |
Why?
| | Endoscopy, Gastrointestinal | 40 | 2023 | 203 | 7.580 |
Why?
| | Gastroenterology | 25 | 2023 | 159 | 7.370 |
Why?
| | Endoscopy, Digestive System | 24 | 2023 | 110 | 7.360 |
Why?
| | Precancerous Conditions | 28 | 2023 | 158 | 7.310 |
Why?
| | Colonoscopy | 32 | 2024 | 204 | 6.050 |
Why?
| | Quality Indicators, Health Care | 17 | 2021 | 287 | 5.810 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 18 | 2020 | 52 | 5.240 |
Why?
| | Gastroesophageal Reflux | 19 | 2023 | 234 | 4.800 |
Why?
| | Colonic Polyps | 20 | 2024 | 67 | 4.480 |
Why?
| | Clinical Competence | 25 | 2024 | 893 | 4.320 |
Why?
| | Esophagus | 21 | 2021 | 225 | 4.260 |
Why?
| | Pancreatic Neoplasms | 22 | 2023 | 731 | 3.740 |
Why?
| | Learning Curve | 13 | 2024 | 63 | 3.410 |
Why?
| | Adenoma | 17 | 2023 | 189 | 3.080 |
Why?
| | Population Surveillance | 11 | 2021 | 392 | 3.020 |
Why?
| | Gastrointestinal Diseases | 9 | 2022 | 182 | 2.950 |
Why?
| | Endoscopy | 15 | 2021 | 246 | 2.650 |
Why?
| | Humans | 270 | 2024 | 114662 | 2.610 |
Why?
| | Biopsy | 23 | 2023 | 1036 | 2.250 |
Why?
| | Colorectal Neoplasms | 14 | 2023 | 615 | 2.200 |
Why?
| | Cholangitis | 5 | 2023 | 19 | 2.030 |
Why?
| | Endoscopic Mucosal Resection | 9 | 2022 | 22 | 2.020 |
Why?
| | Pancreatic Cyst | 4 | 2020 | 47 | 1.980 |
Why?
| | Pancreatitis | 11 | 2024 | 107 | 1.950 |
Why?
| | Guideline Adherence | 5 | 2021 | 490 | 1.810 |
Why?
| | Catheter Ablation | 8 | 2022 | 288 | 1.810 |
Why?
| | Watchful Waiting | 8 | 2021 | 55 | 1.810 |
Why?
| | Prospective Studies | 43 | 2023 | 6219 | 1.770 |
Why?
| | Narrow Band Imaging | 8 | 2022 | 15 | 1.710 |
Why?
| | Bile Duct Neoplasms | 4 | 2021 | 56 | 1.640 |
Why?
| | Pancreatic Diseases | 10 | 2020 | 64 | 1.500 |
Why?
| | Disease Progression | 20 | 2023 | 2380 | 1.490 |
Why?
| | Hyperplasia | 8 | 2024 | 163 | 1.450 |
Why?
| | Middle Aged | 85 | 2024 | 26733 | 1.320 |
Why?
| | Fiducial Markers | 2 | 2019 | 8 | 1.320 |
Why?
| | Stents | 12 | 2024 | 475 | 1.310 |
Why?
| | Sphincterotomy, Endoscopic | 8 | 2021 | 24 | 1.300 |
Why?
| | Pancreas | 9 | 2021 | 276 | 1.260 |
Why?
| | Aged | 67 | 2022 | 19069 | 1.250 |
Why?
| | Education, Medical, Graduate | 6 | 2023 | 368 | 1.200 |
Why?
| | Registries | 8 | 2022 | 1768 | 1.170 |
Why?
| | United States | 38 | 2023 | 12181 | 1.150 |
Why?
| | Ampulla of Vater | 4 | 2023 | 30 | 1.120 |
Why?
| | Male | 98 | 2024 | 55583 | 1.120 |
Why?
| | Choledocholithiasis | 3 | 2023 | 14 | 1.090 |
Why?
| | Benchmarking | 4 | 2022 | 161 | 1.080 |
Why?
| | Esophagectomy | 7 | 2023 | 111 | 1.080 |
Why?
| | Needles | 4 | 2020 | 49 | 1.060 |
Why?
| | Rectum | 2 | 2019 | 153 | 1.050 |
Why?
| | Esophagitis, Peptic | 3 | 2023 | 16 | 1.050 |
Why?
| | Societies, Medical | 8 | 2020 | 663 | 1.040 |
Why?
| | Female | 94 | 2024 | 59493 | 1.040 |
Why?
| | Biopsy, Fine-Needle | 4 | 2017 | 64 | 1.030 |
Why?
| | Ablation Techniques | 3 | 2017 | 29 | 1.020 |
Why?
| | Intestinal Polyps | 2 | 2016 | 15 | 1.020 |
Why?
| | Fellowships and Scholarships | 4 | 2021 | 227 | 1.000 |
Why?
| | Digestive System Diseases | 3 | 2015 | 23 | 0.990 |
Why?
| | Practice Patterns, Physicians' | 6 | 2021 | 1177 | 0.980 |
Why?
| | Biliary Tract Diseases | 5 | 2020 | 32 | 0.950 |
Why?
| | Aptitude | 2 | 2015 | 38 | 0.950 |
Why?
| | Laryngopharyngeal Reflux | 2 | 2021 | 13 | 0.950 |
Why?
| | Gastrointestinal Hemorrhage | 4 | 2023 | 102 | 0.940 |
Why?
| | Observer Variation | 13 | 2017 | 295 | 0.940 |
Why?
| | Pepsin A | 2 | 2021 | 18 | 0.940 |
Why?
| | Self Expandable Metallic Stents | 2 | 2021 | 14 | 0.930 |
Why?
| | Lymph Nodes | 4 | 2015 | 419 | 0.910 |
Why?
| | Practice Guidelines as Topic | 11 | 2021 | 1394 | 0.890 |
Why?
| | Taurine | 1 | 2023 | 41 | 0.870 |
Why?
| | Colonic Pseudo-Obstruction | 2 | 2020 | 3 | 0.870 |
Why?
| | Intestinal Volvulus | 2 | 2020 | 9 | 0.860 |
Why?
| | Esophageal Achalasia | 2 | 2020 | 25 | 0.840 |
Why?
| | Catheterization | 8 | 2023 | 159 | 0.820 |
Why?
| | Disease Management | 3 | 2021 | 560 | 0.820 |
Why?
| | Stomach Diseases | 2 | 2014 | 19 | 0.800 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2023 | 858 | 0.780 |
Why?
| | Rectal Diseases | 2 | 2019 | 17 | 0.780 |
Why?
| | Drainage | 7 | 2023 | 151 | 0.780 |
Why?
| | Cholestasis | 3 | 2021 | 225 | 0.770 |
Why?
| | Deglutition Disorders | 2 | 2021 | 118 | 0.770 |
Why?
| | Teaching Rounds | 1 | 2022 | 64 | 0.760 |
Why?
| | Pancreatectomy | 3 | 2021 | 171 | 0.760 |
Why?
| | Endoscopes | 2 | 2021 | 18 | 0.760 |
Why?
| | Incidence | 16 | 2023 | 2313 | 0.740 |
Why?
| | Sensitivity and Specificity | 19 | 2023 | 1692 | 0.740 |
Why?
| | Equipment Reuse | 1 | 2021 | 11 | 0.730 |
Why?
| | Esophageal Diseases | 2 | 2014 | 24 | 0.730 |
Why?
| | Dilatation | 3 | 2019 | 60 | 0.730 |
Why?
| | Argon Plasma Coagulation | 1 | 2020 | 4 | 0.720 |
Why?
| | Hemostasis, Endoscopic | 1 | 2020 | 1 | 0.710 |
Why?
| | Neoplasm Staging | 7 | 2020 | 1167 | 0.710 |
Why?
| | Treatment Outcome | 22 | 2023 | 9088 | 0.710 |
Why?
| | Early Detection of Cancer | 12 | 2022 | 328 | 0.710 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2017 | 43 | 0.700 |
Why?
| | Retrospective Studies | 34 | 2023 | 12546 | 0.690 |
Why?
| | Heller Myotomy | 1 | 2019 | 1 | 0.690 |
Why?
| | Acetylcholine Release Inhibitors | 1 | 2019 | 3 | 0.690 |
Why?
| | Esophageal Sphincter, Lower | 1 | 2019 | 10 | 0.690 |
Why?
| | Sigmoid Diseases | 1 | 2019 | 10 | 0.680 |
Why?
| | SEER Program | 4 | 2020 | 196 | 0.680 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 23 | 0.680 |
Why?
| | Cholinesterase Inhibitors | 1 | 2019 | 24 | 0.680 |
Why?
| | Carcinoma | 3 | 2021 | 198 | 0.670 |
Why?
| | Proctoscopy | 1 | 2019 | 6 | 0.670 |
Why?
| | Bile Ducts | 3 | 2014 | 68 | 0.660 |
Why?
| | Conservative Treatment | 1 | 2019 | 29 | 0.660 |
Why?
| | Quality of Health Care | 2 | 2021 | 573 | 0.660 |
Why?
| | Racism | 1 | 2021 | 102 | 0.650 |
Why?
| | Botulinum Toxins | 1 | 2019 | 39 | 0.650 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 30 | 0.650 |
Why?
| | Medical Overuse | 1 | 2019 | 31 | 0.650 |
Why?
| | Decompression, Surgical | 1 | 2019 | 93 | 0.640 |
Why?
| | Colonic Neoplasms | 7 | 2022 | 215 | 0.640 |
Why?
| | Referral and Consultation | 3 | 2022 | 632 | 0.620 |
Why?
| | Family Health | 1 | 2019 | 193 | 0.600 |
Why?
| | Radiation Injuries | 1 | 2019 | 128 | 0.600 |
Why?
| | Intestinal Perforation | 2 | 2016 | 39 | 0.600 |
Why?
| | Conflict of Interest | 1 | 2020 | 119 | 0.600 |
Why?
| | Prosthesis Implantation | 1 | 2019 | 138 | 0.590 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 165 | 0.590 |
Why?
| | Pancreatic Ducts | 4 | 2021 | 69 | 0.590 |
Why?
| | Acute Disease | 7 | 2021 | 911 | 0.580 |
Why?
| | Cytological Techniques | 1 | 2017 | 23 | 0.580 |
Why?
| | Risk Factors | 17 | 2024 | 8632 | 0.570 |
Why?
| | Adult | 43 | 2024 | 30544 | 0.560 |
Why?
| | Cohort Studies | 9 | 2023 | 4895 | 0.550 |
Why?
| | Metaplasia | 10 | 2023 | 54 | 0.550 |
Why?
| | Cathartics | 1 | 2016 | 11 | 0.550 |
Why?
| | Documentation | 2 | 2023 | 167 | 0.550 |
Why?
| | Diagnostic Tests, Routine | 1 | 2017 | 87 | 0.540 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 311 | 0.540 |
Why?
| | Hypnotics and Sedatives | 2 | 2020 | 134 | 0.540 |
Why?
| | Conscious Sedation | 2 | 2020 | 78 | 0.540 |
Why?
| | Quality Improvement | 2 | 2021 | 950 | 0.540 |
Why?
| | Specimen Handling | 1 | 2017 | 155 | 0.540 |
Why?
| | Carcinoembryonic Antigen | 2 | 2018 | 37 | 0.540 |
Why?
| | Hospitals | 1 | 2021 | 581 | 0.530 |
Why?
| | Diarrhea | 3 | 2019 | 171 | 0.530 |
Why?
| | Neoplasms | 3 | 2020 | 2097 | 0.530 |
Why?
| | Predictive Value of Tests | 17 | 2019 | 1796 | 0.520 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 25 | 0.510 |
Why?
| | Adenomatous Polyps | 1 | 2015 | 8 | 0.510 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.500 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2014 | 577 | 0.500 |
Why?
| | Pathology, Clinical | 1 | 2015 | 32 | 0.500 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 14 | 0.500 |
Why?
| | Ultrasonography, Interventional | 2 | 2019 | 123 | 0.500 |
Why?
| | Competency-Based Education | 1 | 2015 | 65 | 0.490 |
Why?
| | Jaundice, Obstructive | 1 | 2014 | 3 | 0.490 |
Why?
| | Aged, 80 and over | 19 | 2020 | 6345 | 0.490 |
Why?
| | Aftercare | 4 | 2023 | 186 | 0.480 |
Why?
| | Duodenal Diseases | 1 | 2014 | 9 | 0.480 |
Why?
| | Delphi Technique | 4 | 2024 | 160 | 0.480 |
Why?
| | Hemorrhage | 4 | 2020 | 620 | 0.480 |
Why?
| | Pancreaticoduodenectomy | 1 | 2016 | 133 | 0.470 |
Why?
| | Internship and Residency | 3 | 2021 | 926 | 0.470 |
Why?
| | Intestinal Mucosa | 4 | 2015 | 532 | 0.470 |
Why?
| | Mucous Membrane | 9 | 2015 | 108 | 0.470 |
Why?
| | Foreign-Body Migration | 1 | 2014 | 37 | 0.470 |
Why?
| | Duodenum | 1 | 2014 | 62 | 0.460 |
Why?
| | Colectomy | 1 | 2015 | 86 | 0.460 |
Why?
| | Tomography, X-Ray Computed | 6 | 2020 | 2285 | 0.460 |
Why?
| | Advisory Committees | 5 | 2014 | 208 | 0.460 |
Why?
| | Delivery of Health Care | 1 | 2021 | 833 | 0.460 |
Why?
| | Cholecystectomy | 3 | 2019 | 45 | 0.460 |
Why?
| | Time Factors | 12 | 2021 | 6115 | 0.460 |
Why?
| | Precision Medicine | 1 | 2017 | 337 | 0.450 |
Why?
| | Multimodal Imaging | 1 | 2014 | 88 | 0.450 |
Why?
| | Risk Assessment | 10 | 2020 | 2968 | 0.450 |
Why?
| | Stomach Neoplasms | 3 | 2020 | 65 | 0.440 |
Why?
| | Enteral Nutrition | 3 | 2021 | 159 | 0.430 |
Why?
| | Reproducibility of Results | 16 | 2023 | 2763 | 0.430 |
Why?
| | Polyps | 1 | 2013 | 11 | 0.430 |
Why?
| | Positron-Emission Tomography | 1 | 2014 | 259 | 0.420 |
Why?
| | Liver Neoplasms | 3 | 2023 | 506 | 0.420 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 48 | 0.420 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 38 | 0.420 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2012 | 8 | 0.420 |
Why?
| | Education, Medical, Continuing | 3 | 2022 | 117 | 0.420 |
Why?
| | Pandemics | 6 | 2023 | 1317 | 0.400 |
Why?
| | Health Care Costs | 1 | 2015 | 381 | 0.400 |
Why?
| | Gastroenterologists | 2 | 2022 | 18 | 0.400 |
Why?
| | Multivariate Analysis | 7 | 2021 | 1430 | 0.400 |
Why?
| | Sex Factors | 5 | 2021 | 1715 | 0.380 |
Why?
| | Neuroendocrine Tumors | 3 | 2018 | 85 | 0.380 |
Why?
| | Laparoscopy | 1 | 2015 | 398 | 0.380 |
Why?
| | Manometry | 3 | 2021 | 89 | 0.380 |
Why?
| | Propofol | 1 | 2011 | 43 | 0.380 |
Why?
| | Video Recording | 7 | 2019 | 143 | 0.370 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 338 | 0.370 |
Why?
| | Coronavirus Infections | 3 | 2020 | 330 | 0.360 |
Why?
| | Logistic Models | 7 | 2021 | 1841 | 0.360 |
Why?
| | Pathology, Surgical | 1 | 2010 | 7 | 0.350 |
Why?
| | Hypotension | 1 | 2011 | 116 | 0.350 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2023 | 59 | 0.350 |
Why?
| | Duodenal Neoplasms | 2 | 2023 | 19 | 0.350 |
Why?
| | Cholecystitis | 2 | 2023 | 17 | 0.350 |
Why?
| | Education, Medical | 1 | 2013 | 215 | 0.350 |
Why?
| | Curriculum | 1 | 2015 | 819 | 0.330 |
Why?
| | Diagnostic Techniques, Digestive System | 2 | 2019 | 11 | 0.330 |
Why?
| | Informed Consent | 3 | 2022 | 161 | 0.330 |
Why?
| | Survival Rate | 3 | 2021 | 1644 | 0.320 |
Why?
| | Irritable Bowel Syndrome | 2 | 2019 | 29 | 0.320 |
Why?
| | Hernia, Hiatal | 4 | 2021 | 31 | 0.320 |
Why?
| | Odds Ratio | 4 | 2018 | 953 | 0.320 |
Why?
| | Wandering Spleen | 1 | 2008 | 2 | 0.320 |
Why?
| | Evidence-Based Medicine | 5 | 2021 | 668 | 0.310 |
Why?
| | Surgeons | 2 | 2022 | 239 | 0.310 |
Why?
| | Histocytochemistry | 4 | 2013 | 78 | 0.310 |
Why?
| | Image Enhancement | 6 | 2018 | 159 | 0.310 |
Why?
| | Computer-Assisted Instruction | 4 | 2024 | 62 | 0.310 |
Why?
| | Mass Screening | 5 | 2022 | 1004 | 0.300 |
Why?
| | Tertiary Care Centers | 4 | 2016 | 126 | 0.300 |
Why?
| | Postoperative Complications | 4 | 2021 | 2128 | 0.300 |
Why?
| | Decision Trees | 2 | 2019 | 81 | 0.290 |
Why?
| | Liver Transplantation | 1 | 2014 | 707 | 0.290 |
Why?
| | Microscopy, Confocal | 5 | 2020 | 304 | 0.290 |
Why?
| | Proton Pump Inhibitors | 3 | 2022 | 96 | 0.290 |
Why?
| | Obesity | 4 | 2019 | 2508 | 0.290 |
Why?
| | Malignant Catarrh | 1 | 2006 | 1 | 0.280 |
Why?
| | Fluid Therapy | 2 | 2018 | 123 | 0.280 |
Why?
| | Age Factors | 5 | 2020 | 2894 | 0.280 |
Why?
| | Goats | 1 | 2006 | 26 | 0.280 |
Why?
| | Prevalence | 7 | 2023 | 2251 | 0.280 |
Why?
| | Herpesviridae | 1 | 2006 | 21 | 0.270 |
Why?
| | Recurrence | 3 | 2020 | 935 | 0.270 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 2 | 2019 | 15 | 0.270 |
Why?
| | Picolinic Acids | 1 | 2006 | 3 | 0.260 |
Why?
| | Carrier State | 1 | 2006 | 54 | 0.260 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2006 | 22 | 0.260 |
Why?
| | Follow-Up Studies | 10 | 2015 | 4411 | 0.260 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2017 | 211 | 0.260 |
Why?
| | Decision Support Techniques | 3 | 2019 | 355 | 0.260 |
Why?
| | Hypoxia | 1 | 2011 | 957 | 0.250 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1342 | 0.250 |
Why?
| | Cattle Diseases | 1 | 2005 | 15 | 0.240 |
Why?
| | Constriction, Pathologic | 5 | 2020 | 208 | 0.240 |
Why?
| | Heartburn | 2 | 2021 | 11 | 0.240 |
Why?
| | DNA, Viral | 1 | 2006 | 350 | 0.240 |
Why?
| | Escherichia coli Infections | 1 | 2005 | 100 | 0.230 |
Why?
| | Educational Measurement | 3 | 2023 | 243 | 0.230 |
Why?
| | Program Evaluation | 2 | 2020 | 822 | 0.230 |
Why?
| | Sheep | 1 | 2006 | 764 | 0.230 |
Why?
| | Indomethacin | 1 | 2024 | 70 | 0.220 |
Why?
| | Bile Duct Diseases | 2 | 2014 | 15 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 2 | 2022 | 2085 | 0.220 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2023 | 24 | 0.220 |
Why?
| | Kaplan-Meier Estimate | 3 | 2020 | 811 | 0.220 |
Why?
| | Feasibility Studies | 5 | 2020 | 740 | 0.220 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2023 | 11 | 0.210 |
Why?
| | Ergonomics | 1 | 2023 | 23 | 0.210 |
Why?
| | Sphincter of Oddi | 2 | 2021 | 4 | 0.210 |
Why?
| | Biomedical Research | 2 | 2020 | 585 | 0.210 |
Why?
| | Cytodiagnosis | 2 | 2020 | 29 | 0.210 |
Why?
| | Cholelithiasis | 1 | 2023 | 31 | 0.210 |
Why?
| | Medicare | 2 | 2021 | 665 | 0.210 |
Why?
| | Microsurgery | 1 | 2023 | 59 | 0.210 |
Why?
| | Weight Loss | 2 | 2021 | 642 | 0.210 |
Why?
| | Fluorouracil | 1 | 2023 | 152 | 0.210 |
Why?
| | Appendiceal Neoplasms | 1 | 2022 | 14 | 0.210 |
Why?
| | Carcinoid Tumor | 1 | 2022 | 25 | 0.200 |
Why?
| | Gastrectomy | 2 | 2023 | 82 | 0.200 |
Why?
| | Surgical Instruments | 3 | 2022 | 47 | 0.200 |
Why?
| | Disease Outbreaks | 1 | 2005 | 307 | 0.200 |
Why?
| | Dietary Supplements | 1 | 2006 | 460 | 0.200 |
Why?
| | Health Care Surveys | 3 | 2020 | 539 | 0.200 |
Why?
| | Lithotripsy | 2 | 2019 | 40 | 0.190 |
Why?
| | Esophageal Sphincter, Upper | 1 | 2021 | 5 | 0.190 |
Why?
| | Biopsy, Needle | 2 | 2020 | 182 | 0.190 |
Why?
| | Proton Pumps | 1 | 2021 | 8 | 0.190 |
Why?
| | Professional Practice Location | 2 | 2019 | 26 | 0.190 |
Why?
| | Pancreatic Pseudocyst | 2 | 2018 | 13 | 0.190 |
Why?
| | Escherichia coli | 1 | 2005 | 720 | 0.190 |
Why?
| | Single-Blind Method | 5 | 2014 | 258 | 0.190 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2021 | 12 | 0.180 |
Why?
| | Internationality | 2 | 2020 | 143 | 0.180 |
Why?
| | Trefoil Factor-3 | 1 | 2020 | 5 | 0.180 |
Why?
| | Consensus | 3 | 2018 | 537 | 0.180 |
Why?
| | Gastric Outlet Obstruction | 1 | 2020 | 7 | 0.180 |
Why?
| | Formative Feedback | 2 | 2024 | 22 | 0.180 |
Why?
| | Radiography, Abdominal | 2 | 2012 | 32 | 0.180 |
Why?
| | Midazolam | 1 | 2020 | 43 | 0.180 |
Why?
| | Oral Submucous Fibrosis | 1 | 2020 | 1 | 0.180 |
Why?
| | Equipment Contamination | 1 | 2021 | 54 | 0.180 |
Why?
| | Stomach | 2 | 2012 | 102 | 0.180 |
Why?
| | Varicose Veins | 1 | 2020 | 14 | 0.180 |
Why?
| | Cost-Benefit Analysis | 3 | 2015 | 544 | 0.180 |
Why?
| | Laparotomy | 2 | 2012 | 103 | 0.180 |
Why?
| | Betacoronavirus | 2 | 2020 | 250 | 0.180 |
Why?
| | Emergencies | 1 | 2021 | 146 | 0.170 |
Why?
| | United Arab Emirates | 1 | 2020 | 5 | 0.170 |
Why?
| | Esophageal and Gastric Varices | 1 | 2020 | 31 | 0.170 |
Why?
| | Morbidity | 1 | 2021 | 280 | 0.170 |
Why?
| | Perception | 1 | 2022 | 311 | 0.170 |
Why?
| | Myotomy | 1 | 2019 | 8 | 0.170 |
Why?
| | Body Fluids | 1 | 2020 | 58 | 0.170 |
Why?
| | Research Design | 2 | 2020 | 928 | 0.170 |
Why?
| | Neostigmine | 1 | 2019 | 4 | 0.170 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2020 | 31 | 0.170 |
Why?
| | Cecum | 1 | 2019 | 32 | 0.170 |
Why?
| | Colostomy | 1 | 2019 | 26 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2023 | 197 | 0.170 |
Why?
| | Pancreatitis, Chronic | 2 | 2019 | 40 | 0.170 |
Why?
| | Survival Analysis | 2 | 2015 | 1211 | 0.170 |
Why?
| | Disease Transmission, Infectious | 1 | 2020 | 55 | 0.170 |
Why?
| | Accreditation | 1 | 2020 | 76 | 0.170 |
Why?
| | ROC Curve | 4 | 2015 | 442 | 0.170 |
Why?
| | Saliva | 1 | 2021 | 187 | 0.170 |
Why?
| | Disinfection | 1 | 2021 | 106 | 0.170 |
Why?
| | Dissection | 2 | 2020 | 51 | 0.170 |
Why?
| | Mirizzi Syndrome | 1 | 2019 | 1 | 0.160 |
Why?
| | Injections, Intramuscular | 1 | 2019 | 116 | 0.160 |
Why?
| | Urinary Calculi | 1 | 2019 | 11 | 0.160 |
Why?
| | Chronic Disease | 3 | 2019 | 1578 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2020 | 144 | 0.160 |
Why?
| | Ascites | 1 | 2019 | 32 | 0.160 |
Why?
| | Anastomotic Leak | 1 | 2019 | 27 | 0.160 |
Why?
| | Feedback | 1 | 2019 | 144 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2020 | 309 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2021 | 200 | 0.160 |
Why?
| | Infection Control | 1 | 2020 | 135 | 0.160 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1481 | 0.160 |
Why?
| | Esophageal Mucosa | 1 | 2018 | 17 | 0.160 |
Why?
| | Plastics | 2 | 2018 | 35 | 0.150 |
Why?
| | Fluoroscopy | 1 | 2019 | 139 | 0.150 |
Why?
| | Mortality | 1 | 2020 | 287 | 0.150 |
Why?
| | Prognosis | 3 | 2017 | 3329 | 0.150 |
Why?
| | Esophagogastric Junction | 3 | 2021 | 42 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2021 | 3003 | 0.150 |
Why?
| | Clinical Protocols | 1 | 2019 | 233 | 0.150 |
Why?
| | Palliative Care | 2 | 2021 | 642 | 0.150 |
Why?
| | Gallstones | 1 | 2018 | 28 | 0.150 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.150 |
Why?
| | Colonoscopes | 3 | 2014 | 5 | 0.150 |
Why?
| | Quality-Adjusted Life Years | 2 | 2015 | 101 | 0.150 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2017 | 13 | 0.150 |
Why?
| | Markov Chains | 2 | 2015 | 114 | 0.150 |
Why?
| | Reference Standards | 1 | 2018 | 159 | 0.150 |
Why?
| | Aneurysm, False | 1 | 2018 | 45 | 0.150 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2538 | 0.140 |
Why?
| | Cardia | 2 | 2007 | 2 | 0.140 |
Why?
| | MicroRNAs | 2 | 2015 | 600 | 0.140 |
Why?
| | Medical Staff Privileges | 1 | 2017 | 4 | 0.140 |
Why?
| | Credentialing | 1 | 2017 | 12 | 0.140 |
Why?
| | Education | 1 | 2017 | 95 | 0.140 |
Why?
| | Optical Imaging | 2 | 2018 | 54 | 0.140 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 49 | 0.140 |
Why?
| | Research | 1 | 2020 | 394 | 0.140 |
Why?
| | Patient Discharge | 1 | 2023 | 772 | 0.140 |
Why?
| | Leiomyoma | 1 | 2017 | 44 | 0.140 |
Why?
| | Immunoassay | 1 | 2017 | 95 | 0.140 |
Why?
| | Upper Gastrointestinal Tract | 1 | 2016 | 5 | 0.140 |
Why?
| | Bariatric Surgery | 1 | 2019 | 161 | 0.140 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 4622 | 0.130 |
Why?
| | Global Health | 1 | 2018 | 287 | 0.130 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2016 | 60 | 0.130 |
Why?
| | Chemoprevention | 2 | 2014 | 88 | 0.130 |
Why?
| | Physicians | 1 | 2024 | 772 | 0.130 |
Why?
| | India | 2 | 2006 | 134 | 0.130 |
Why?
| | Antibiotic Prophylaxis | 1 | 2016 | 96 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2018 | 1226 | 0.130 |
Why?
| | Metals | 3 | 2023 | 106 | 0.120 |
Why?
| | Teaching | 1 | 2017 | 213 | 0.120 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 52 | 0.120 |
Why?
| | Intestinal Fistula | 1 | 2014 | 11 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 196 | 0.120 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 159 | 0.120 |
Why?
| | Cryosurgery | 1 | 2015 | 52 | 0.120 |
Why?
| | Colorectal Surgery | 1 | 2014 | 21 | 0.120 |
Why?
| | Primary Health Care | 2 | 2022 | 1512 | 0.120 |
Why?
| | Health Status | 1 | 2019 | 722 | 0.110 |
Why?
| | Combined Modality Therapy | 2 | 2015 | 1121 | 0.110 |
Why?
| | Goblet Cells | 1 | 2013 | 16 | 0.110 |
Why?
| | Suture Techniques | 1 | 2014 | 115 | 0.110 |
Why?
| | Patient Participation | 1 | 2017 | 359 | 0.110 |
Why?
| | Propensity Score | 1 | 2015 | 224 | 0.110 |
Why?
| | Prosthesis Failure | 1 | 2014 | 115 | 0.110 |
Why?
| | Animals, Newborn | 2 | 2006 | 778 | 0.110 |
Why?
| | Light | 2 | 2013 | 336 | 0.110 |
Why?
| | Cattle | 2 | 2006 | 921 | 0.110 |
Why?
| | Multidetector Computed Tomography | 1 | 2013 | 26 | 0.110 |
Why?
| | Polymerase Chain Reaction | 2 | 2006 | 993 | 0.110 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2014 | 211 | 0.100 |
Why?
| | Jejunum | 1 | 2012 | 24 | 0.100 |
Why?
| | Decision Making | 3 | 2023 | 782 | 0.100 |
Why?
| | Equipment Design | 3 | 2021 | 508 | 0.100 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2016 | 284 | 0.100 |
Why?
| | Mediastinum | 1 | 2012 | 22 | 0.100 |
Why?
| | Abdomen | 1 | 2012 | 99 | 0.100 |
Why?
| | Anesthetics, Intravenous | 1 | 2011 | 27 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1075 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2011 | 198 | 0.090 |
Why?
| | Proteomics | 1 | 2017 | 836 | 0.090 |
Why?
| | Patient Selection | 1 | 2015 | 641 | 0.090 |
Why?
| | Guidelines as Topic | 1 | 2012 | 243 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1040 | 0.090 |
Why?
| | Adrenal Glands | 1 | 2011 | 66 | 0.090 |
Why?
| | Veterans | 1 | 2021 | 1249 | 0.090 |
Why?
| | Software | 1 | 2014 | 530 | 0.090 |
Why?
| | Body Mass Index | 3 | 2013 | 1958 | 0.090 |
Why?
| | Young Adult | 7 | 2020 | 10466 | 0.090 |
Why?
| | Intestines | 1 | 2013 | 326 | 0.090 |
Why?
| | Esophagitis | 2 | 2007 | 65 | 0.090 |
Why?
| | Esophageal pH Monitoring | 1 | 2009 | 23 | 0.080 |
Why?
| | North America | 2 | 2020 | 256 | 0.080 |
Why?
| | Gastric Acid | 1 | 2009 | 13 | 0.080 |
Why?
| | Antacids | 1 | 2009 | 15 | 0.080 |
Why?
| | Remission Induction | 1 | 2009 | 233 | 0.080 |
Why?
| | Adolescent | 7 | 2024 | 17841 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2014 | 681 | 0.080 |
Why?
| | Patient Care Planning | 1 | 2009 | 139 | 0.070 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2017 | 9 | 0.070 |
Why?
| | Hematoporphyrin Photoradiation | 1 | 2007 | 1 | 0.070 |
Why?
| | Colonography, Computed Tomographic | 1 | 2007 | 3 | 0.070 |
Why?
| | Gastric Fundus | 1 | 2007 | 3 | 0.070 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 17 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 931 | 0.070 |
Why?
| | Natural Orifice Endoscopic Surgery | 2 | 2016 | 26 | 0.070 |
Why?
| | Gastritis | 1 | 2007 | 84 | 0.070 |
Why?
| | Plasmapheresis | 1 | 2006 | 22 | 0.070 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 223 | 0.060 |
Why?
| | Dairying | 1 | 2005 | 7 | 0.060 |
Why?
| | Biomarkers | 3 | 2015 | 3408 | 0.060 |
Why?
| | Hospitalization | 2 | 2023 | 1751 | 0.060 |
Why?
| | Seasons | 1 | 2006 | 442 | 0.060 |
Why?
| | Administration, Rectal | 1 | 2024 | 5 | 0.060 |
Why?
| | Virulence | 1 | 2005 | 227 | 0.060 |
Why?
| | Image-Guided Biopsy | 2 | 2015 | 31 | 0.060 |
Why?
| | DNA Primers | 1 | 2005 | 510 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 750 | 0.060 |
Why?
| | Glypicans | 1 | 2023 | 9 | 0.060 |
Why?
| | DNA, Bacterial | 1 | 2005 | 311 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1637 | 0.050 |
Why?
| | United Kingdom | 1 | 2023 | 226 | 0.050 |
Why?
| | Tumor Burden | 2 | 2015 | 259 | 0.050 |
Why?
| | Feces | 1 | 2005 | 373 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2006 | 447 | 0.050 |
Why?
| | Appendectomy | 1 | 2022 | 67 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 211 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 374 | 0.050 |
Why?
| | Technology | 1 | 2022 | 79 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4408 | 0.050 |
Why?
| | Colonic Diseases | 2 | 2014 | 25 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 56 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 299 | 0.050 |
Why?
| | Lifting | 1 | 2020 | 4 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 158 | 0.050 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
| | Cough | 1 | 2021 | 107 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 385 | 0.040 |
Why?
| | Granuloma | 1 | 2020 | 83 | 0.040 |
Why?
| | Pilot Projects | 3 | 2011 | 1373 | 0.040 |
Why?
| | Rural Population | 1 | 2023 | 446 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 49 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 2012 | 440 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 119 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 188 | 0.040 |
Why?
| | Network Meta-Analysis | 1 | 2019 | 15 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 462 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 636 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 304 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 446 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 250 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2020 | 227 | 0.040 |
Why?
| | Coloring Agents | 1 | 2018 | 72 | 0.040 |
Why?
| | Communication | 1 | 2024 | 744 | 0.040 |
Why?
| | Quality of Life | 1 | 2009 | 2353 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2019 | 135 | 0.040 |
Why?
| | Cyst Fluid | 1 | 2018 | 27 | 0.040 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2018 | 46 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2018 | 140 | 0.040 |
Why?
| | Hospitals, University | 1 | 2018 | 172 | 0.040 |
Why?
| | Cancer Pain | 1 | 2017 | 20 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 379 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2017 | 61 | 0.040 |
Why?
| | Granular Cell Tumor | 1 | 2017 | 7 | 0.040 |
Why?
| | Lipoma | 1 | 2017 | 15 | 0.040 |
Why?
| | Choristoma | 1 | 2017 | 23 | 0.030 |
Why?
| | Choledochal Cyst | 1 | 2016 | 17 | 0.030 |
Why?
| | Nerve Block | 1 | 2017 | 60 | 0.030 |
Why?
| | Biliary Tract Neoplasms | 1 | 2016 | 20 | 0.030 |
Why?
| | Gastroscopes | 1 | 2016 | 3 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 2710 | 0.030 |
Why?
| | Duodenoscopes | 1 | 2016 | 7 | 0.030 |
Why?
| | Embolism, Air | 1 | 2016 | 11 | 0.030 |
Why?
| | Child, Preschool | 2 | 2022 | 9114 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2186 | 0.030 |
Why?
| | Algorithms | 2 | 2017 | 1468 | 0.030 |
Why?
| | Cholangitis, Sclerosing | 1 | 2016 | 66 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 800 | 0.030 |
Why?
| | Child | 3 | 2021 | 18412 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2021 | 480 | 0.030 |
Why?
| | Animals | 2 | 2006 | 31699 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2362 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 382 | 0.030 |
Why?
| | Equipment Failure | 1 | 2014 | 106 | 0.030 |
Why?
| | Pain | 1 | 2019 | 705 | 0.030 |
Why?
| | Pathology | 1 | 2013 | 20 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2796 | 0.030 |
Why?
| | Health Status Indicators | 1 | 2014 | 156 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1125 | 0.030 |
Why?
| | Community Health Centers | 1 | 2013 | 54 | 0.030 |
Why?
| | Community Health Services | 1 | 2014 | 212 | 0.030 |
Why?
| | Color | 1 | 2013 | 74 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 242 | 0.030 |
Why?
| | Adenoma, Villous | 1 | 2012 | 2 | 0.030 |
Why?
| | Gastroscopy | 1 | 2011 | 18 | 0.020 |
Why?
| | Sentinel Surveillance | 1 | 2011 | 38 | 0.020 |
Why?
| | Digestive System Neoplasms | 1 | 2011 | 8 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 305 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 118 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 411 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 430 | 0.020 |
Why?
| | Risk | 1 | 2013 | 812 | 0.020 |
Why?
| | Genetic Markers | 1 | 2011 | 320 | 0.020 |
Why?
| | Overweight | 1 | 2013 | 471 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 923 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 768 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4099 | 0.020 |
Why?
| | Motor Activity | 1 | 2013 | 640 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2009 | 511 | 0.020 |
Why?
| | Geography | 1 | 2008 | 177 | 0.020 |
Why?
| | Diagnostic Equipment | 1 | 2007 | 3 | 0.020 |
Why?
| | Selenium | 1 | 2007 | 31 | 0.020 |
Why?
| | Helicobacter Infections | 1 | 2007 | 25 | 0.020 |
Why?
| | Helicobacter pylori | 1 | 2007 | 30 | 0.020 |
Why?
| | Fraud | 1 | 2007 | 8 | 0.020 |
Why?
| | Electrocoagulation | 1 | 2007 | 38 | 0.020 |
Why?
| | Gastric Mucosa | 1 | 2007 | 46 | 0.020 |
Why?
| | Laser Coagulation | 1 | 2007 | 54 | 0.020 |
Why?
| | Quality Control | 1 | 2007 | 144 | 0.020 |
Why?
| | Capillaries | 1 | 2007 | 91 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1629 | 0.020 |
Why?
| | Risk Management | 1 | 2007 | 89 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2007 | 293 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 683 | 0.020 |
Why?
| | Infant | 1 | 2018 | 7961 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 275 | 0.010 |
Why?
| | Health Policy | 1 | 2007 | 334 | 0.010 |
Why?
| | Monocytes | 1 | 2007 | 502 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 1879 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1078 | 0.010 |
Why?
| | Comorbidity | 1 | 2007 | 1448 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2319 | 0.010 |
Why?
| | Neutrophils | 1 | 2007 | 1176 | 0.010 |
Why?
| | Smoking | 1 | 2007 | 1381 | 0.010 |
Why?
| | Diet | 1 | 2007 | 1080 | 0.010 |
Why?
|
|
Wani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|